Showing results (151-160 of 180) with videos related to
Sort By:
Pageof 18
Liver International : Official Journal of the International Association for the Study of the Liver|January 24, 2025
Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFNα-2a as Treatment for Chronic Hepatitis DeltaPietro Lampertico, Pavel O Bogomolov, Vladimir Chulanov, et al.Journal of Hepatology|July 22, 2014
Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumaratePatrick Marcellin, Maria Buti, Zahari Krastev, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 21, 2017
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral TherapyIra M Jacobson, Mary K Washington, Maria Buti, et al.Gastroenterology|January 28, 2014
Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNAHenry L Y Chan, Chi Kuen Chan, Aric Josun Hui, et al.Alimentary Pharmacology & Therapeutics|August 12, 2025
Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of TreatmentGrace Lai-Hung Wong, Edward Gane, Calvin Q Pan, et al.Antimicrobial Agents and Chemotherapy|December 25, 2003
Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected childrenRohan Hazra, Frank M Balis, Antonella N Tullio, et al.Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2014
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml)Scott Fung, Stuart C Gordon, Zahary Krastev, et al.Antimicrobial Agents and Chemotherapy|July 25, 2018
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B InfectionAndrea L Cathcart, Henry Lik-Yuen Chan, Neeru Bhardwaj, et al.Liver International : Official Journal of the International Association for the Study of the Liver|December 9, 2024
Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48Tarik Asselah, Pietro Lampertico, Soo Aleman, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|July 31, 2025
Switching to tenofovir alafenamide in virally-suppressed chronic hepatitis B patients with renal/hepatic impairment: Phase 2 study sub-analysis from TaiwanChun-Jen Liu, Young-Suk Lim, Chi-Yi Chen, et al.Pageof 18